Numelvi is a pioneering brand in animal health, specializing in innovative treatments for canine allergic dermatitis. Their flagship product, Numelvi (atinvicitinib tablets), is the first second-generation Janus kinase (JAK) inhibitor exclusively designed for dogs. This groundbreaking medication provides highly selective and effective relief from itching and inflammation associated with allergies, ensuring a rapid response in as little as two to four hours. Safe for dogs and puppies six months and older, Numelvi is an ideal first-line treatment that simplifies administration with just one daily dose.

In addition to Numelvi, the brand offers a range of veterinary products, including Allflex, Bravecto, and Nobivac, catering to both pet owners and veterinary professionals. Numelvi is committed to advancing animal welfare and sustainability through responsible practices and partnerships, reinforcing their dedication to improving animal health globally. As a trusted name among animal health professionals, Numelvi represents a new way forward in enhancing the well-being of dogs everywhere.